Literature DB >> 27550851

Haematological cancer: Carfilzomib is superior to bortezomib in rMM.

Peter Sidaway.   

Abstract

Entities:  

Year:  2016        PMID: 27550851     DOI: 10.1038/nrclinonc.2016.136

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.

Authors:  P Moreau; D Joshua; W-J Chng; A Palumbo; H Goldschmidt; R Hájek; T Facon; H Ludwig; L Pour; R Niesvizky; A Oriol; L Rosiñol; A Suvorov; G Gaidano; T Pika; K Weisel; V Goranova-Marinova; H H Gillenwater; N Mohamed; S Aggarwal; S Feng; M A Dimopoulos
Journal:  Leukemia       Date:  2016-07-04       Impact factor: 11.528

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.